U of T Engineering is a leader in health care engineering. Together with doctors, medical researchers, policymakers and industry, we are helping people around the world live longer, healthier lives.
To enable future success in the evolving bioproducts industry, we developed specialized programs to teach students to translate their bioengineeiring research into successful startups.
- Brain-Machine Interfacing
- Cell Manufacturing
- Disease Modeling & Therapeutics
- Health-care Engineering
- Heart Research
- Next-generation Medical Devices
- Regenerative Medicine
- Synthetic Biology
Medicine by Design undertakes transformative research in regenerative medicine and cell therapy.
TBEP drives research at the interface of engineering and medicine. With a roster of multidisciplinary investigators, researchers develop strategies that will repair or regenerate heart muscle.
CHE is a leader in interdisciplinary research and education in healthcare engineering. Its research directly impacts healthcare organizations and partners in practice.
SOCAAR is a world-class centre for environmental research committed to innovation in producing a broad, trans-disciplinary and actionable understanding of the origins, characteristics, environmental impact, and human health consequences of atmospheric aerosols.
Study Human Health at U of T Engineering
The Institute of Biomaterials & Biomedical Engineering (IBBME) — a multidisciplinary research community of engineering, medicine and dentistry investigators — offers research-based graduate programs at both the Master’s and Doctoral levels, as well as a Master of Health Science (MHSc) in Clinical Engineering and a Master of Engineering (MEng) that focuses on the design of biomedical devices. At the undergraduate level, engineering students can minor in Biomedical Engineering or Bioengineering, and Engineering Science students can major in Biomedical Systems Engineering.
Using their novel organ-on-a-chip platform, a U of T Engineering research team has identified a molecule with the potential to combat one of the most severe complications of COVID-19 infections.
The molecule, a novel anti-inflammatory peptide called QHREDGS, does not act on the virus directly. Instead, it works to prevent a potentially life-threatening immune reaction known as a cytokine storm.
Cytokine storms are known to occur in some patients with COVID-19, as well as other illnesses